Shahbah Doaaa, Hassan Tamer, Morsy Saeed, Saadany Hosam El, Fathy Manar, Al-Ghobashy Ashgan, Elsamad Nahla, Emam Ahmed, Elhewala Ahmed, Ibrahim Boshra, Gebaly Sherief El, Sayed Hany El, Ahmed Hanan
Department of Pediatrics Department of Clinical Pathology, Zagazig University, Zagazig, Egypt.
Medicine (Baltimore). 2017 Mar;96(11):e6352. doi: 10.1097/MD.0000000000006352.
Dietary supplementation with magnesium (Mg) in addition to classical therapies for diabetes may help in prevention or delaying of diabetic complications.We aimed to evaluate the status of serum Mg in children with type 1 diabetes and assessing its relationship to glycemic control and lipid profile. Then evaluating the effect of oral Mg supplementation on glycemic control and lipid parameters.We included 71 children at Pediatric Endocrinology Outpatient Clinic, Zagazig University, Egypt with type 1 diabetes and assessed HBA1c, lipid profile, and serum Mg at the start of study. Patients with serum Mg level < 1.7 mg/dL were given 300 mg Mg oxide for 3 months. After that we reevaluated HBA1c, lipid profile, and serum Mg in all patients.The study included 71 patients with type 1 diabetes (32 males and 39 females); their mean age was 9.68 ± 3.99 years. The mean serum Mg level was 1.83 ± .27 mg/dL. Hypomagnesemia was detected in 28.2% study patients. Serum Mg was found to be positively correlated with high density lipoprotein, mean corpuscular volume and platelet count (P < 0.001), and negatively correlated with age, HbA1c, triglycerides, total cholesterol, low density lipoprotein, and duration of diabetes (P < 0.001). There was significant reduction in HBA1c in group given Mg supplementation. HBA1c was initially 10.11% ± 0.87%. After 3 months of oral Mg supplementation it is reduced to 7.88% ± 0.42% (P < 0.001). There was statistically significant difference in lipid parameters in hypomagnesemic diabetic patients before and after Mg supplementation with significant reduction in serum triglycerides, LDL, and total cholesterol following Mg supplementation with P < 0.001. Although HDL shows a significant increase after Mg supplementation in hypomagnesemic diabetic children with P < 0.001.Correction of hypomagnesemia in type 1 diabetic children with oral Mg supplements is associated with optimization of glycemic control and reduction of atherogenic lipid fraction as well as increase in protective lipid fraction.
除糖尿病的传统治疗方法外，补充镁（Mg）有助于预防或延缓糖尿病并发症。我们旨在评估1型糖尿病患儿的血清镁水平，并评估其与血糖控制和血脂谱的关系。然后评估口服镁补充剂对血糖控制和血脂参数的影响。我们纳入了埃及扎加齐格大学儿科内分泌门诊的71名1型糖尿病患儿，并在研究开始时评估了糖化血红蛋白（HBA1c）、血脂谱和血清镁。血清镁水平<1.7mg/dL的患者给予300mg氧化镁，持续3个月。之后，我们重新评估了所有患者的HBA1c、血脂谱和血清镁。该研究包括71名1型糖尿病患者（32名男性和39名女性）；他们的平均年龄为9.68±3.99岁。平均血清镁水平为1.83±0.27mg/dL。28.2%的研究患者检测到低镁血症。发现血清镁与高密度脂蛋白、平均红细胞体积和血小板计数呈正相关（P<0.001），与年龄、糖化血红蛋白、甘油三酯、总胆固醇、低密度脂蛋白和糖尿病病程呈负相关（P<0.001）。补充镁的组糖化血红蛋白有显著降低。糖化血红蛋白最初为10.11%±0.87%。口服镁补充剂3个月后降至7.88%±0.42%（P<0.001）。低镁血症糖尿病患者补充镁前后血脂参数有统计学显著差异，补充镁后血清甘油三酯、低密度脂蛋白和总胆固醇显著降低，P<0.001。虽然在低镁血症糖尿病儿童补充镁后高密度脂蛋白有显著增加，P<0.001。口服镁补充剂纠正1型糖尿病儿童的低镁血症与优化血糖控制、降低致动脉粥样硬化脂质成分以及增加保护性脂质成分有关。
